EpiVax and CUBRC Awarded FDA Contract Worth $2M for Development of Control Peptides for Immunogenicity Risk Assessment Assays Supporting Regulatory Filings of Generic Peptide Drugs

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

EpiVax-CUBRC-Awarded

More Like This

PR Newswire associated0

EpiVax Drives Immunogenicity Innovation in 2024: Year in Review

PR Newswire associated0

EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements

Business Wire logo

ViiV Healthcare to present data for its next generation of ultra long-acting treatments for HIV

PR Newswire associated0

Novel Immunogenicity Risk Assessment Platform, ISPRI, Facilitates Biologic Therapeutics Development

ACCESSWIRE logo

ProteinQure Announces A Breakthrough Therapeutic with Remarkable Efficacy in Heterogenous Patient-Derived Xenograft Models of Triple-Negative Breast Cancer to be presented at AACR

PR Newswire associated0

Fapon Biopharma Announces FDA Approval of IND for FP008, a First-in-Class Immunotherapy for Solid Tumors

PR Newswire associated0

CordenPharma and Viking Therapeutics Sign Long-Term Strategic Partnership for Integrated Supply of GLP-1 Peptides, Injectables and Oral Formulations

PR Newswire associated0

EnGeneIC Selects Global CDMO BioCina to Advance Their Ground-Breaking Cancer Treatment